Effect of YAP1-inhibition in Surgical Wounds.

Sponsor
Jöri Pünchera
Study ID
NCT06944249
Phase
PHASE1/PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Scar Formation

Eligibility Criteria

Sex
ALL
Age
18 Years - 55 Years
Healthy Volunteers
Not accepted

Interventions

  • NaCl (placebo) — DRUG
    During the safety margin excision, the placebo (NaCl) will be injected into the wound before suturing.
  • Verteporfin Injection — DRUG
    During the safety margin excision, the study drug (Verteporfin) will be injected into the wound before suturing.

Study Details

When we get injured, our body naturally tries to heal. In adults, this healing often leads to scars - thick, stiff tissue known as fibrotic tissue. Unlike normal tissue, fibrotic tissue doesn't function properly and can cause serious health problems, depending on the affected organ. Once it forms, fibrosis is usually permanent. A good example of the fibrosis process is the healing of our skin: after a cut or surgery, the resulting scar is a type of fibrosis. Special cells called fibroblasts are key players in this process. Our study looks at a drug called verteporfin, which is already approved both in Europe and the U.S. Previous research on mice and human cells suggests it can reduce or even prevent fibrosis. We are now testing, clinically, histologically and by scRNA-seq, whether injecting verteporfin into the skin during wound healing, specifically after surgical procedures, can prevent thick, rigid scars from forming. Since the skin is easy to observe and sample, it offers a great model for studying this. Will verteporfin have an impact on how surgical wounds heal? That's what we aim to find out.

Key Dates

Start date
May 8, 2025
Status verified
Apr 2025
Primary completion
Apr 30, 2026
Completion
Jul 31, 2026

Study Design

Enrollment
24 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: Study arm (verteporfin)
  • Placebo Comparator: Placebo arm

Primary Outcome Measure

Quantification of the profibrotic mesenchymal fibroblast subpopulation in the study group compared to the placebo group. [ Time Frame: There are 90 +/- 10 days between visit 1 and visit 4. ]

Central Contacts

Related Studies